

A blue-tinted background image showing several glass test tubes in a laboratory setting. A pipette is positioned above one of the tubes, with a single drop of liquid about to fall into it.

**Præsentation af halvårsregnskabet  
30. juni 2023 i Pharma Equity Group**

# H1 2023

## Agenda

1. High-lights fra H1 2023
2. H1 2023 halvårsrapport for Pharma Equity Group
3. Finansielle forventninger til resten af 2023
4. Finansiell kalender 2023






**1.**  
**High-Lights fra H1 2023**

# H1 2023

## Highlights for primært Q2 2023

- SM 37, Udstedelse af patent på behandling med selskabets sårhelende lægemiddelkombination
- SM 34, Frigivelse af indledende data fra det igangværende studie på patienter, som lider af Pauchitis
- Illikviditet i aktien og høj volatilitet i aktien
- Antal aktionærer er gået fra 1.165 – 1.600 svarende til en vækst på 37%
- Portinho Fordringen - Kapitalberedskabsplan
- Ændringer i bestyrelsen
- Markedsførings- og kommunikationsplan
- Ny Corporate Identity film
- Mere investorrettet hjemmeside
- Nyt internt studie til investorpræsentationer



# Direktions & Bestyrelse aktiebeholdning i PEG 30. juni 2023

Management shareholding and marked value 30 June 2023		
Name	Number of shares	Value 30 June 2023 (TDKK)
Thomas Kaas Selsø, CEO, PEG	1,822,474	1,048
Christian Vinding Thomsen, Chairman of the Board, PEG	1,233,605	709
Lars Rosenkrantz Gundorph, Board Member, PEG	21,351,475	12,277
Troels Peter Troelsen, Board Member, Reponex	21,944,945	12,618
Charlotte Pahl, Board Member, Reponex	3,694,210	2,124





**2.**  
**H1 2023 kvartalsrapport for  
Pharma Equity Group**

# H1 2023

## Kvartalsrapport for Pharma Equity Group

- Transaktionen med Reponex er at betragte som en omvendt transaktion, hvor det regnskabsmæssigt vises som om Reponex overtager PEG
- I resultatopgørelsen er PEG medtaget i H1 fra 24. marts – 30. juni 2023
- I resultatopgørelsen er Reponex medtaget for hele H1 2023
- I resultatopgørelsen er sammenligningstal for Q2, H1 og for hele 2022 kun for Reponex
- Q2-2023 resultat og totalindkomst for Pharma Equity Group (PEG): TDKK -4,346 (H1-2023: TDKK -7,210)
- Research and development cost (PEG): TDKK -2,514 (H1-2023: TDKK -4,124)
- Administrative cost (PEG): TDKK -2,420 (H1-2023: TDKK -4,206)

<b>Statement of comprehensive income</b>					
	PEG Group*	Reponex	PEG Group*	Reponex	Reponex
	01-04-2023 - 30-06-2023	01-04-2022 - 30-06-2022	01-01-2023 - 30-06-2023	01-01-2022 - 30-06-2022	01-01-2022 - 31-12-2022
Note	(unaudited) TDKK	(unaudited) TDKK	(unaudited) TDKK	(unaudited) TDKK	(audited) TDKK
3	<b>Revenue</b>	0	0	0	0
	Production costs	0	0	0	0
	<b>Gross profit</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
	Research and development costs	-2,514	-1,494	-4,124	-6,263
	Administrative costs	-2,420	-1,392	-4,206	-5,780
	<b>Operating profit/loss (EBIT)</b>	<b>-4,934</b>	<b>-2,886</b>	<b>-8,329</b>	<b>-12,043</b>
	Financial income	370	0	370	0
	Financial expenses	-452	-6	-455	-22
	<b>Profit/loss before tax</b>	<b>-5,016</b>	<b>-2,892</b>	<b>-8,415</b>	<b>-12,065</b>
4	Tax on profit/loss for the period	670	431	1,205	804
	<b>Net profit/loss for the period</b>	<b>-4,346</b>	<b>-2,461</b>	<b>-7,210</b>	<b>-10,210</b>
	Other comprehensive income/loss	0	0	0	0
	<b>Total comprehensive income/loss</b>	<b>-4,346</b>	<b>-2,461</b>	<b>-7,210</b>	<b>-10,210</b>
9	Earnings per share (EPS basic), DKK	-0.00	-0.00	-0.01	-0.00
9	Diluted earnings per share (EPS-D), DKK	-0.00	-0.00	-0.01	-0.00

\* PEG Group comprehensive income for H1 2023 and Q2 2023 consists of Reponex for H1 2023 and PEG for the period 24 March 2023 - 30 June 2023.

# H1 2023

## Kvartalsrapport for Pharma Equity Group

- Balancen for H1 2023 indeholder både PEG og Reponex
- Balancens sammenligningstal indeholder kun Reponex
- Samlet balancesum (PEG): MDKK 85,6
- Tilgodehavende Portinho: MDKK 62,8 (MDKK 74,5) Fair value regulering af egenkapitalen i PEG 24/3 fordelt på aktiver (MDKK -10,1)
- Likviditet: MDKK 3,5

<b>Statement of financial position</b>			
ASSETS	PEG Group 30-06-2023 <i>(unaudited)</i>	Reponex 30-06-2022 <i>(unaudited)</i>	Reponex 31-12-2022 <i>(audited)</i>
Note	TDKK	TDKK	TDKK
<b>Non-current assets</b>			
6 Intangible assets	11,815	12,842	12,328
6 Tangible assets	64	0	0
6 Right-of-use assets	438	722	582
Tax receivable	1,205	804	0
<b>Total non-current assets</b>	<b>13,522</b>	<b>14,368</b>	<b>12,910</b>
<b>Current assets</b>			
Inventories	1,592	1,633	1,587
7 Receivable Portinho S.A.	62,772	0	0
Other receivables	2,233	874	802
Prepaid expenses	138	106	0
Current tax receivable	1,855	1,483	1,855
Cash and cash equivalents	3,512	6,690	2,830
<b>Total current assets</b>	<b>72,103</b>	<b>10,786</b>	<b>7,074</b>
<b>Total assets</b>	<b>85,625</b>	<b>25,153</b>	<b>19,984</b>



# H1 2023

## Kvartalsrapport for Pharma Equity Group

- Egenkapital: MDKK 55,9
- (Market Value 30/6-2023: MDKK 588)
- Kortfristede forpligtelser MDKK 29,6

EQUITY AND LIABILITIES		30-06-2023	30-06-2022	31-12-2022
Note		TDKK	TDKK	TDKK
	Share capital	1,022,964	830	830
	Reserve for capitalised development costs	6,896	8,488	7,409
	Other reserves	-973,945	13,643	9,140
11	<b>Total equity</b>	<b>55,914</b>	<b>22,960</b>	<b>17,379</b>
	Lease liabilities	124	451	295
	<b>Total long-term liabilities</b>	<b>124</b>	<b>451</b>	<b>295</b>
	Trade payables	6,748	1,043	1,606
	Bank debt	7,406	0	0
	Financial loans	7,083	0	0
14	Loans from related parties	6,582	0	0
	Lease liabilities	314	270	286
	Other liabilities	1,454	428	418
	<b>Total current liabilities</b>	<b>29,586</b>	<b>1,742</b>	<b>2,310</b>
	<b>Total liabilities</b>	<b>29,710</b>	<b>2,193</b>	<b>2,605</b>
	<b>Total equity and liabilities</b>	<b>85,625</b>	<b>25,153</b>	<b>19,984</b>



**3.**  
**Pharma Equity Group's  
finansielle forventninger til  
resten af 2023**

# Finansielle forventninger til resten af 2023

## Strategi og forventninger til 2023, udmeldt i selskabsmeddelelse nr. 17, fastholdes

- Det forventes, at der i Reponex Pharmaceuticals A/S, investeres mere i udviklingsprojekter i 2023 end i 2022
- Der er i Q2 2023 investeret i styrkelse af organisationen i både Reponex Pharmaceuticals og i Pharma Equity Group, på flere områder
  - CMC
  - Clinic
  - Finance
- Der påtænkes ikke at investere yderligere organisatorisk i 2023
- Forventningerne for 2023 om et koncernresultat før skat på MDKK -18 til MDKK -22 fastholdes



**4.**  
**Finansiel kalender 2023**

# Finansiell kalender 2023

## Seneste opdateret Marts 2023

March 13, 2023      Deadline for shareholder proposal – Annual General Meeting

March 31, 2023      Annual Report 2022

April 27, 2023      Annual General Meeting

May 10, 2023      Interim Report – for the three-month period ended March 31, 2023

August 16, 2023      Interim Report – for the six-month period ended June 30, 2023